Foundation Medicine is a molecular information company dedicated to increasing personalised healthcare via a deep understanding of the molecular changes that contribute to diseases such as cancer.
Foundation Medicines offers a full suite of comprehensive genomic profiling (CGP) assays to identify the molecular alterations in an individual patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.
In Australia, Roche’s pharmaceutical division is the licensed distributor of FoundationOne®CDx, FoundationOne®Liquid CDx and FoundationOne®Heme, offering CGP services and decision support tools that may inform clinical care in cancer.
Healthcare professionals who would like more information about Roche Foundation Medicine services may go to
Genomic profiling (also known as genetic sequencing) uses laboratory and computational methods to read the blueprint of cancer cells (the tumour DNA sequence). Compared to normal cells, cancer cells have a blueprint that contain errors. These errors lead to abnormal growth of tumour cells. Understanding what errors are present in the tumour cells may be useful in informing treatment options.
Patients wanting more information about cancer tumour testing should speak with their doctor. Only medical doctors are able to order a Foundation Medicine test.
FoundationOneCDx is for solid tumours; FoundationOneHeme is for haematologic cancers or sarcomas. FoundationOneLiquid is a liquid biopsy test for solid tumours. FoundationOne reports may contain information regarding treatments that may be unavailable or may not be approved for use in Australia, or clinical trials that may not be operating locally. FoundationOne reports may contain information regarding treatments that may be unavailable or may not be approved for use in Australia, or clinical trials that may not be operating locally.
Molecular information and genomic analysis play an increasingly important role in medicine and diagnostics solutions, especially for cancer patients.